APA
Stone J. H., Carruthers M. N., Topazian M. D., Khosroshahi A., Witzig T. E., Wallace Z. S., Hart P. A., Deshpande V., Smyrk T. C. & Chari S. (20151001). Response to: 'Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years' by Yamamoto et al. : Annals of the rheumatic diseases.
Chicago
Stone John H, Carruthers Mollie N, Topazian Mark D, Khosroshahi Arezou, Witzig Thomas E, Wallace Zachary S, Hart Phillip A, Deshpande Vikram, Smyrk Thomas C and Chari Suresh. 20151001. Response to: 'Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years' by Yamamoto et al. : Annals of the rheumatic diseases.
Harvard
Stone J. H., Carruthers M. N., Topazian M. D., Khosroshahi A., Witzig T. E., Wallace Z. S., Hart P. A., Deshpande V., Smyrk T. C. and Chari S. (20151001). Response to: 'Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years' by Yamamoto et al. : Annals of the rheumatic diseases.
MLA
Stone John H, Carruthers Mollie N, Topazian Mark D, Khosroshahi Arezou, Witzig Thomas E, Wallace Zachary S, Hart Phillip A, Deshpande Vikram, Smyrk Thomas C and Chari Suresh. Response to: 'Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years' by Yamamoto et al. : Annals of the rheumatic diseases. 20151001.